Arcus Biosciences, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   ARC-10 · Zimberelimab and Domvanalimab in Lung Cancer

   Trial completed

   Also in this update: Primary completion date changed from estimate of May 2027 to Sep 17, 2026

   Arcus Biosciences, Inc.·Phase 2· NCT04736173· Registry history of NCT04736173 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Minor

   ARC-27 · AB801 Monotherapy and Combination Therapy · Advanced…ARC-27 · AB801 Monotherapy and Combination Therapy · Advanced Malignancies

   Trial completed

   Also in this update: Final enrollment: 29 participants (planned 91); Primary completion date changed from estimate of Nov 2026 to Apr 29, 2026

   Arcus Biosciences, Inc.·Phase 1· NCT06120075· Registry history of NCT06120075 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

3. Minor

   Casdatifan and Cabozantinib Versus Placebo and Cabozantinib…Casdatifan and Cabozantinib Versus Placebo and Cabozantinib · Advanced Clear Cell Renal Cell Carcinoma

   Trial sites expanded: 176 → 183 locations

   Arcus Biosciences, Inc.·Phase 3· NCT07011719· Registry history of NCT07011719 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.